Annals of Oncology · 2016 · 28 citations · 19 references
MedicineOncologyPharmacologyCancer PharmacologyClinical PharmacologyOncology PharmacotherapyGenitourinary Cancer PharmacotherapyMetastatic Disease TreatmentProstate CancerChemotherapy Dose-limiting ToxicityDose-limiting Toxicity AssessmentMaximum Tolerated EffectPhase Ii InvestigationProstate Cancer Hormonal TherapyProstate-specific Antigen - Targeted TherapySafety Profile CharacterizationSerious Adverse Events
19
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Oncology, Pharmacology +17